ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Chipscreen Biosciences and Jiangsu HengRui Medicine side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

Chipscreen BiosciencesJiangsu HengRui Medicine
studies on the registry421,065
open to participants now11306
phase 3 studies under way4105
reach primary completion within a year3130
programswith a study of their own in two years6156+1 named only

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseChipscreen BiosciencesJiangsu HengRui Medicine
Phase 1

Chipscreen Biosciences: 2 of its 6 programs at phase 1

  1. CS08399phase 1
  2. CS231295phase 1
33%

Jiangsu HengRui Medicine: 53 of its 156 programs at phase 1

  1. Rifampinphase 1
  2. HRS-5817phase 1
  3. HRS-2189phase 1
  4. SHR-2017phase 1
  5. Anti-DLL3 Antibody-drug Conjugate IDE849phase 1

and 48 more — sign in to see them all

34%
Phase 2

Chipscreen Biosciences: 1 of its 6 programs at phase 2

  1. CS32582phase 2
17%

Jiangsu HengRui Medicine: 50 of its 156 programs at phase 2

  1. SHR-1139phase 2
  2. SHR-1826phase 2
  3. SHR-2173phase 2
  4. SHR-9839phase 2
  5. HRS-4508phase 2

and 45 more — sign in to see them all

32%
Phase 3

Chipscreen Biosciences: 3 of its 6 programs at phase 3

  1. chiauranibphase 3
  2. tucidinostatphase 3
  3. chiglitazarphase 3
50%

Jiangsu HengRui Medicine: 51 of its 156 programs at phase 3

  1. adebrelimabphase 3
  2. trastuzumab rezetecanphase 3
  3. Anti-CTLA-4 Monoclonal Antibody SHR-8068phase 3
  4. ribupatidephase 3
  5. notiretatug rezetecanphase 3

and 46 more — sign in to see them all

33%
Approved, new studies00%

Jiangsu HengRui Medicine: 2 of its 156 programs at approved, new studies

  1. vunakizumabapproved, new study
  2. remimazolam tosylateapproved, new study
1%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Chipscreen Biosciences2 readouts · 0 phase 3···

Chipscreen Biosciences, Feb ’27: 1 program whose next study reaches primary completion

  1. chiauranibphase 3 · Feb 28 · NCT06492915
······

Chipscreen Biosciences, Sep ’27: 1 program whose next study reaches primary completion

  1. CS32582phase 2 · Sep 18 · NCT07129382
·
Jiangsu HengRui Medicine75 readouts · 11 phase 3

Jiangsu HengRui Medicine, Nov ’26: 2 programs whose next study reaches primary completion

  1. HRS-1780phase 3 · Nov 0 · NCT07470983
  2. SHR-1681phase 2 · Nov 0 · NCT06737731

Jiangsu HengRui Medicine, Dec ’26: 32 programs whose next study reaches primary completion, 4 in phase 3

  1. adebrelimabphase 3 · Dec 0 · NCT05482568
  2. Anti-DLL3 Antibody-drug Conjugate IDE849phase 1 · Dec 0 · NCT06443489
  3. BP102phase 3 · Dec 0 · NCT06915142
  4. drotokibartphase 3 · Dec 0 · NCT07688772
  5. HRS-1596phase 1 · Dec 0 · NCT07841860

and 27 more — sign in to see them all

Jiangsu HengRui Medicine, Jan ’27: 4 programs whose next study reaches primary completion, 1 in phase 3

  1. RSS0393phase 3 · Jan 0 · NCT07543224
  2. SHR 3201phase 1 · Jan 0 · NCT07889349
  3. SHR-4375phase 2 · Jan 0 · NCT07298772
  4. HRS-5817phase 1 · Jan 30 · NCT07238647

Jiangsu HengRui Medicine, Feb ’27: 8 programs whose next study reaches primary completion

  1. FH-006phase 3 · Feb 0 · NCT07136142
  2. HRS-5346phase 2 · Feb 0 · NCT07767513
  3. HRS-8080phase 3 · Feb 0 · NCT07876596
  4. KRAS G12D Inhibitor HRS-4642phase 3 · Feb 0 · NCT07906691
  5. RSS0343phase 2 · Feb 0 · NCT07940829

and 3 more — sign in to see them all

Jiangsu HengRui Medicine, Mar ’27: 8 programs whose next study reaches primary completion, 3 in phase 3

  1. Anti-CD79b Antibody-drug Conjugate SHR-A1912phase 3 · Mar 0 · NCT06929624
  2. HRS-1893phase 3 · Mar 0 · NCT07269717
  3. HRS-4139phase 1 · Mar 0 · NCT07802964
  4. HRS-4729phase 2 · Mar 0 · NCT07690826
  5. ivarmacitinibphase 3 · Mar 0 · NCT07251595

and 3 more — sign in to see them all

Jiangsu HengRui Medicine, Apr ’27: 6 programs whose next study reaches primary completion

  1. HRS-4029phase 2 · Apr 0 · NCT07739160
  2. HRS-5632phase 2 · Apr 0 · NCT07185776
  3. SHR-1703phase 3 · Apr 0 · NCT07701239
  4. SHR-2173phase 2 · Apr 0 · NCT07354932
  5. SHR-4602phase 2 · Apr 0 · NCT06704828

and 1 more — sign in to see them all

Jiangsu HengRui Medicine, May ’27: 1 program whose next study reaches primary completion

  1. SHR-4712phase 1 · May 0 · NCT06993116

Jiangsu HengRui Medicine, Jun ’27: 5 programs whose next study reaches primary completion, 1 in phase 3

  1. HRS-7249phase 2 · Jun 0 · NCT07308392
  2. HRS8179phase 3 · Jun 0 · NCT06732648
  3. SHR-1819phase 3 · Jun 0 · NCT07321951
  4. SHR-1918phase 3 · Jun 0 · NCT07308392
  5. SHR-9803phase 2 · Jun 0 · NCT06906731

Jiangsu HengRui Medicine, Jul ’27: 5 programs whose next study reaches primary completion

  1. Anti-CTLA-4 Monoclonal Antibody SHR-8068phase 3 · Jul 0 · NCT07682272
  2. ruzinuradphase 3 · Jul 0 · NCT07362355
  3. aumolertinibphase 3 · Jul 30 · NCT05503888
  4. retlirafusp alfaphase 3 · Jul 30 · NCT05503888
  5. SHR-9539phase 1 · Jul 31 · NCT06484777
·

Jiangsu HengRui Medicine, Sep ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. HRS-4508phase 2 · Sep 0 · NCT07003321
  2. garetatug rezetecanphase 3 · Sep 20 · NCT06649292

Jiangsu HengRui Medicine, Oct ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. HRS-5965phase 3 · Oct 0 · NCT07014826
  2. SHR-2524phase 1 · Oct 0 · NCT07478302
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Chipscreen Biosciences

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 1

Jiangsu HengRui Medicine

New programs 11

Reached a new phase 4

  • SHR-3167phase 3 · Oct 28 · Diabetes Mellitus, Type 2
  • HRS-6209phase 3 · Oct 14 · Breast Neoplasms
  • HRS-7172phase 2 · Sep 2 · Pancreatic Neoplasms
  • FH-006phase 3 · Aug 25 · Lung Neoplasms

Study stopped 0

None

Primary completion later 6

Where they overlap

Conditions where at least two of them have programs: 10 in all. A program counts in each condition its studies name most.

ConditionChipscreen BiosciencesJiangsu HengRui Medicine
Carcinoma, Non-Small-Cell Lungboth · compare here

Chipscreen Biosciences in Carcinoma, Non-Small-Cell Lung: 2 programs

  1. tucidinostatphase 3
  2. CS08399phase 1

Their studies: Chipscreen Biosciences’ studies of Carcinoma, Non-Small-Cell Lung in search

Breast Neoplasmsboth · compare here

Chipscreen Biosciences in Breast Neoplasms: 1 program

  1. tucidinostatphase 3

Their studies: Chipscreen Biosciences’ studies of Breast Neoplasms in search

Jiangsu HengRui Medicine in Breast Neoplasms: 9 programs

  1. adebrelimabphase 3
  2. trastuzumab rezetecanphase 3
  3. HRS-8080phase 3
  4. ruzaltatug rezetecanphase 3
  5. HRS-6209phase 3

and 4 more — sign in to see them all

Their studies: Jiangsu HengRui Medicine’s studies of Breast Neoplasms in search

Diabetes Mellitus, Type 2both · compare here

Chipscreen Biosciences in Diabetes Mellitus, Type 2: 1 program

  1. chiglitazarphase 3

Their studies: Chipscreen Biosciences’ studies of Diabetes Mellitus, Type 2 in search

Jiangsu HengRui Medicine in Diabetes Mellitus, Type 2: 7 programs

  1. ribupatidephase 3
  2. SHR-3167phase 3
  3. HRS-1780phase 3
  4. Safiglipronphase 3
  5. HR17031phase 3

and 2 more — sign in to see them all

Their studies: Jiangsu HengRui Medicine’s studies of Diabetes Mellitus, Type 2 in search

Neoplasmsboth · compare here

Chipscreen Biosciences in Neoplasms: 1 program

  1. CS231295phase 1

Their studies: Chipscreen Biosciences’ studies of Neoplasms in search

Jiangsu HengRui Medicine in Neoplasms: 6 programs

  1. adebrelimabphase 3
  2. zeprumetostatphase 3
  3. efserakefusp alfaphase 3
  4. Trastuzumabphase 3
  5. risvutatug rezetecanphase 2

and 1 more — sign in to see them all

Their studies: Jiangsu HengRui Medicine’s studies of Neoplasms in search

Psoriasisboth · compare here

Chipscreen Biosciences in Psoriasis: 1 program

  1. CS32582phase 2

Their studies: Chipscreen Biosciences’ studies of Psoriasis in search

Jiangsu HengRui Medicine in Psoriasis: 4 programs

  1. RSS0393phase 3
  2. SHR-1139phase 2
  3. HRS-4139phase 1
  4. vunakizumabapproved, new study

Their studies: Jiangsu HengRui Medicine’s studies of Psoriasis in search

Small Cell Lung Carcinomaboth · compare here

Chipscreen Biosciences in Small Cell Lung Carcinoma: 1 program

  1. chiauranibphase 3

Their studies: Chipscreen Biosciences’ studies of Small Cell Lung Carcinoma in search

Jiangsu HengRui Medicine in Small Cell Lung Carcinoma: 3 programs

  1. adebrelimabphase 3
  2. risvutatug rezetecanphase 2
  3. Anti-DLL3 Antibody-drug Conjugate IDE849phase 1

Their studies: Jiangsu HengRui Medicine’s studies of Small Cell Lung Carcinoma in search

Lymphoma, Non-Hodgkinboth · compare here

Chipscreen Biosciences in Lymphoma, Non-Hodgkin: 2 programs

  1. chiauranibphase 3
  2. tucidinostatphase 3

Their studies: Chipscreen Biosciences’ studies of Lymphoma, Non-Hodgkin in search

Jiangsu HengRui Medicine in Lymphoma, Non-Hodgkin: 1 program

  1. HRS-3738phase 1

Their studies: Jiangsu HengRui Medicine’s studies of Lymphoma, Non-Hodgkin in search

Ovarian Neoplasmsboth · compare here

Chipscreen Biosciences in Ovarian Neoplasms: 1 program

  1. chiauranibphase 3

Their studies: Chipscreen Biosciences’ studies of Ovarian Neoplasms in search

Jiangsu HengRui Medicine in Ovarian Neoplasms: 2 programs

  1. trastuzumab rezetecanphase 3
  2. SHR-2004phase 3

Their studies: Jiangsu HengRui Medicine’s studies of Ovarian Neoplasms in search

Melanomaboth · compare here

Chipscreen Biosciences in Melanoma: 1 program

  1. tucidinostatphase 3

Their studies: Chipscreen Biosciences’ studies of Melanoma in search

Jiangsu HengRui Medicine in Melanoma: 1 program

  1. Rifampinphase 1

Their studies: Jiangsu HengRui Medicine’s studies of Melanoma in search

Renal Insufficiencyboth · compare here

Chipscreen Biosciences in Renal Insufficiency: 1 program

  1. chiglitazarphase 3

Their studies: Chipscreen Biosciences’ studies of Renal Insufficiency in search

Jiangsu HengRui Medicine in Renal Insufficiency: 1 program

  1. Edaravonephase 1

Their studies: Jiangsu HengRui Medicine’s studies of Renal Insufficiency in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

No gene two of them both target, among the programs whose target is known.

A target, or a pathogen for a vaccine, known for: Chipscreen Biosciences 2 of 6 · Jiangsu HengRui Medicine 67 of 156 programs (18 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (Jiangsu HengRui Medicine: 1).